pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
siRNA · news · pharmadog
← back to siRNA
News · siRNA
111
stories
Oct 20, 26
Alnylam bulls and bears fight it out after business-shaking guidance cut
biospace
Oct 19, 26
Merck KGaA makes noise in hematology with $1.1B Silence buy
biospace
Oct 19, 26
Merck KGaA bets on RNAi with $1.3B Silence buyout
biopharma dive
Oct 19, 26
Merck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3B
endpoints
Oct 19, 26
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
fiercebiotech
Oct 16, 26
City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
biospace
Oct 16, 26
China looks to ban foreign acquisitions of critical biopharma platforms
fiercebiotech
Oct 16, 26
Next-gen RNAi drugmaker City prices $200M IPO
biopharma dive
Oct 16, 26
City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field
endpoints
Oct 16, 26
City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq
fiercebiotech
Oct 15, 26
Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop
biospace
Oct 14, 26
Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
biopharma dive
Oct 13, 26
Roche extends China deal streak with $1B pact for RNAi obesity drug
biopharma dive
Oct 13, 26
Roche expands obesity R&D footprint with Rona deal worth $1B+
biospace
Oct 13, 26
Roche's seventh China deal this year is a $1.2B obesity pact with Rona Therapeutics
endpoints
Oct 13, 26
Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race
fiercebiotech
Oct 12, 26
Undecimal Bio launches with $18M to take siRNA beyond liver disease
endpoints
Oct 9, 26
City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut
endpoints
Oct 9, 26
TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
biospace
Oct 9, 26
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
Oct 7, 26
TCGX launches $600M fund to bankroll Asian biotechs
fiercebiotech
Oct 6, 26
TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
fiercebiotech
Oct 5, 26
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset
biospace
Oct 2, 26
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
biospace
Sep 30, 26
GSK continues to stock up on Wave's RNA drugs with liver-focused program
fiercebiotech
Sep 25, 26
STAT+: Lilly wins approval for once-weekly insulin shot
stat
Sep 25, 26
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
biospace
Sep 25, 26
Alnylam alumni lead RNAi biotech City Therapeutics to IPO filing
endpoints
Sep 25, 26
ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentum
endpoints
Sep 25, 26
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
← prev
page 2 of 4
next →